
Pfizer moves forward with its hopes for a monthly obesity drug
Pfizer took its next steps Tuesday in its attempted resurrection in the obesity market. The pharma firm said that an experimental weight loss drug, …

STAT flipped this story into The top headlines in pharma•1h
Related storyboards
More stories from Obesity
More stories from Pfizer
The Wall Street Journal.flipped into Latest From the WSJPfizer Sales Fall on Continued Lower Covid-19 Drug Demand
The drugmaker said sales fell to $17.56 billion in the fourth quarter PfizerPFE0.83%increase; green up pointing triangle reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline. The drugmaker reported a loss of $1.65 billion, or 29 cents a share, …
Pfizer beats fourth-quarter profit estimates on strong drug demand
Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner Eliquis helped offset fading sales of its COVID products. The upbeat results land as Pfizer navigates falling demand for its COVID-19 products …
Join the flipboard community
Discover, collect, and share stories for all your interests
Open in appMore stories from Finance
StringersHubflipped into StringersHub VideosIndia: Structural lapses alleged as water tank slab collapse sends shockwaves through city
Lucknow, Uttar Pradesh, India - February 02, 2026 The sudden collapse of a slab of an under-construction water tank in Valsad city has caused widespread concern across the district. The incident has triggered a political storm with allegations of corruption and administrative failure. Statements made by leaders of the Valsad Municipality have further intensified the debate and drawn public attention. Restriction: Not Distributable in Germany.
Finboldflipped into Cryptocurrency NewsBlackRock dumps over $600M of these two cryptocurrencies in a day
Institutional outflows, which are among the primary causes of the ongoing cryptocurrency market sell-off, continued on Monday, February 2, with …








